AEON Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.63 million compared to USD 52.56 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | +9.72% | -11.24% | -78.06% |
May. 16 | AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024 | CI |
May. 16 | AEON Biopharma, Inc. Announces Executive Changes | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.06% | 61.28M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023